Compare ASTLW & VRXAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTLW | VRXAW |
|---|---|---|
| Founded | 1901 | N/A |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | 2025 |
| Metric | ASTLW | VRXAW |
|---|---|---|
| Price | $0.01 | $0.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 37.7K | 9.7K |
| Earning Date | 02-18-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.00 | $0.07 |
| 52 Week High | $0.34 | $0.23 |
| Indicator | ASTLW | VRXAW |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 38.20 |
| Support Level | $0.00 | N/A |
| Resistance Level | $0.01 | $0.10 |
| Average True Range (ATR) | 0.00 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 58.73 | 4.48 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.